Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2011 1
2014 1
2015 1
2016 4
2017 4
2018 4
2020 2
2021 6
2022 4
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
A positive feedback loop controls Toxoplasma chronic differentiation.
Licon MH, Giuliano CJ, Chan AW, Chakladar S, Eberhard JN, Shallberg LA, Chandrasekaran S, Waldman BS, Koshy AA, Hunter CA, Lourido S. Licon MH, et al. Among authors: chakladar s. Nat Microbiol. 2023 May;8(5):889-904. doi: 10.1038/s41564-023-01358-2. Epub 2023 Apr 20. Nat Microbiol. 2023. PMID: 37081202 Free PMC article.
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, Goldman JD, Saraiva JFK, Chakladar S, Marconi VC; COV-BARRIER Study Group. Ely EW, et al. Among authors: chakladar s. Lancet Respir Med. 2022 Apr;10(4):327-336. doi: 10.1016/S2213-2600(22)00006-6. Epub 2022 Feb 3. Lancet Respir Med. 2022. PMID: 35123660 Free PMC article. Clinical Trial.
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group. Marconi VC, et al. Among authors: chakladar s. Lancet Respir Med. 2021 Dec;9(12):1407-1418. doi: 10.1016/S2213-2600(21)00331-3. Epub 2021 Sep 1. Lancet Respir Med. 2021. PMID: 34480861 Free PMC article. Clinical Trial.
Baricitinib and primary biliary cholangitis.
Gordon SC, Trudeau S, Regev A, Uhas JM, Chakladar S, Pinto-Correia A, Gottlieb K, Schlichting D. Gordon SC, et al. Among authors: chakladar s. J Transl Autoimmun. 2021 Jun 1;4:100107. doi: 10.1016/j.jtauto.2021.100107. eCollection 2021. J Transl Autoimmun. 2021. PMID: 34195587 Free PMC article.
Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S, Batt K, Kuharic M, Bullano M, Caicedo J, Chakladar S, Markan R, Farahbakhshian S. Xing S, et al. Among authors: chakladar s. J Manag Care Spec Pharm. 2023 Jun;29(6):626-634. doi: 10.18553/jmcp.2023.29.6.626. J Manag Care Spec Pharm. 2023. PMID: 37276033 Free PMC article.
Quantification of joint mobility limitation in adult type 1 diabetes.
Phatak S, Mahadevkar P, Chaudhari KS, Chakladar S, Jain S, Dhadge S, Jadhav S, Shah R, Bhalerao A, Patil A, Ingram JL, Goel P, Yajnik CS. Phatak S, et al. Among authors: chakladar s. Front Endocrinol (Lausanne). 2023 Nov 6;14:1238825. doi: 10.3389/fendo.2023.1238825. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027132 Free PMC article.
Morphing rhesus monkey vocalizations.
Chakladar S, Logothetis NK, Petkov CI. Chakladar S, et al. J Neurosci Methods. 2008 May 15;170(1):45-55. doi: 10.1016/j.jneumeth.2007.12.023. Epub 2008 Jan 17. J Neurosci Methods. 2008. PMID: 18289695
36 results